CytomX Therapeutics (CTMX) Cash from Investing Activities (2014 - 2026)

CytomX Therapeutics' Cash from Investing Activities history runs 13 years deep, the most recent figure standing at -$192.8 million for Q1 2026.

• Quarterly Cash from Investing Activities fell 730.07% year-over-year to -$192.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$283.1 million (down 431.48% YoY) and the FY2025 annual result came in at -$59.7 million, down 159.92% from the prior year.
• Cash from Investing Activities was -$192.8 million for Q1 2026 at CytomX Therapeutics, down from -$14.4 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $99.8 million in Q4 2022 and bottomed at -$192.8 million in Q1 2026.
• A 5-year average of -$12.1 million and a median of $439000.0 in 2025 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities jumped 40842.04% — and 2023, when it sank 19824.18%.
• CytomX Therapeutics' Cash from Investing Activities stood at $99.8 million in 2022, then plunged by 87.11% to $12.9 million in 2023, then climbed by 17.64% to $15.1 million in 2024, then sank by 195.27% to -$14.4 million in 2025, then slumped by 1236.97% to -$192.8 million in 2026.
• Business Quant data shows CTMX's Cash from Investing Activities at -$192.8 million in Q1 2026, -$14.4 million in Q4 2025, and $439000.0 in Q3 2025.